-
Neurocrine's Phase 2 Disappointment: Why The Company's Down, But Not Out
Wednesday, May 24, 2017 - 3:34pm | 292Read More...Neurocrine Biosciences, Inc. (NASDAQ: NBIX) shares fell sharply Wednesday following a disappointing phase 2 study of Ingrezza (valbenazine), a pediatric Tourette's syndrome drug. The company announced after Tuesday's close that Ingrezza didn't show a statistically significant difference on...
-
Approval For Neurocrine's Ingrezza Was No Surprise, But Lack Of Warning Label A Big Advantage Over Teva
Wednesday, April 12, 2017 - 1:40pm | 291Read More...Neurocrine Biosciences, Inc. (NASDAQ: NBIX) investors got a pleasant surprise when the FDA approved the company’s Ingrezza drug for treatment of tardive dyskinesia (TD). While the approval itself was expected, Baird analyst Brian Skorney says the FDA’s generous labeling puts the drug at...
-
Neurocrine Outperforms Even Bullish Estimates Of Ingrezza Approval Upside
Wednesday, April 12, 2017 - 12:57pm | 404Read More...Shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) soared by more than 20 percent Wednesday after the U.S. Food and Drug Administration granted approval for the company's Ingrezza therapy. Ingrezza is used by adults with tardive dyskinesia (TD) and has become the first treatment option...
-
Neurocrine Biosciences Achieves Best Case Scenario With Ingrezza Approval
Wednesday, April 12, 2017 - 10:18am | 368Read More...BMO Capital Markets picked Neurocrine Biosciences, Inc.. (NASDAQ: NBIX) to Outperform expectations on Wednesday, one day after the the U.S. Food and Drug Administration approved the pharmaceutical company’s drug for the treatment of tardive dyskinesia, a neurological disorder. It was the...
-
7 Biotech Catalysts Remaining In January
Friday, January 13, 2017 - 3:08pm | 488Read More...Biotech stocks are regaining some lost momentum after Wednesday's Trump-inspired selloff that took a toll on the sentiment on pharma sector. The weakness was so stark that it made CNBC's Brian Sullivan tweet that biotechs/healthcare was the only sector to have been left out of what seemed...
